96% cheaper, Avastin is just as effective as Eylea against eye disorder

11 May 2017

A clinical trial has found that the oncology drug Avastin (bevacizumab) is about as effective as Eylea (aflibercept) in treating central retinal vein occlusion (CRVO), an eye condition.

For years, ophthalmologists have used Roche’s (ROG: SIX) bowel cancer drug Avastin off-label to treat macular degeneration, and related conditions, owing to its ability to prevent the blood vessel growth responsible for these disorders.

Data from the trial reveal that after six monthly injections, treatment with either drug improved visual acuity to the same extent on average.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK